Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
Kelly
Paul J
PJ
Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Weiss
Stephanie E
SE
Sher
David J
DJ
Perez-Atayde
Antonio R
AR
Dal Cin
Paola
P
Choueiri
Toni K
TK
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib